Aesica Awarded NEPIC Industry Award
News Jan 30, 2014
Aesica has announced that one of its employees, Helen Taylor, Corporate HR Manager, has won the NEPIC 2014 Young Achiever Accolade award within the Pharmaceutical category.
Helen was recently promoted to the role of Corporate HR Manager with a specific focus on employee development, skills gaps and talent acquisition. Helen joined Aesica in 2009 as Senior HR Advisor, swiftly progressing to Corporate HR Manager.
She has provided HR support to multiple Aesica sites, being seconded for 3 months to the company’s Monheim, Germany site as an Aesica Ambassador following an acquisition in 2011.
Helen gained a first class honours degree in Human Resource Management at Northumbria University.
The NEPIC (Northeast of England Process Industry Cluster) Annual Awards are designed to recognize the success and achievements of members operating in the hi-tech manufacturing marketplace including the chemical, pharmaceutical, petrochemical and biotechnology sectors among others. The awards provide a platform from which to celebrate the vital contribution that the manufacturing and process industries are making to the regional, national and global economy.
Speaking of her award, Helen commented: “It is a great privilege to be recognized by the NEPIC with this young achiever accolade. People skills are as important as technical skills in the pharmaceutical contract manufacturing market and this award is reflective of the high HR standards that are applied across Aesica. I am proud to be part of the Aesica HR team and look forward to continuing to play my part in the company’s success.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE